Canaccord raised the firm’s price target on Bioventus to $8 from $7 and keeps a Buy rating on the shares. The firm believes the improvements in Q1 and higher growth expectations going forward in PT and SS are encouraging, and initiatives in place are consistent with the company’s goals andwith operating and commercial execution beginning to show leverage and an attractive valuation, the firm increased its target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS:
- Bioventus sees FY24 EPS 25c-33c, consensus 16c
- Bioventus reports Q1 EPS (7c) vs ($2.24) last year
- Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
- Bioventus price target raised to $9 from $6 at Craig-Hallum
- Bioventus, Inc. on the Brink: Navigating Financial Control Challenges and Investor Confidence
